$1300VNV.
WORLD Journal of SURGERY @ 1998 by the Société Internationale de Chirurgie
O
XEIPOUPTIKH
Adrenocortical Carcinoma: Surgery and Mitotane for Treatment and Steroid Profiles for Follow-up
A. Khorram-Manesh, M.D.,1 H. Ahlman, M.D., Ph.D.,1 S. Jansson, M.D., Ph.D.,1 B. Wängberg, M.D., Ph.D.,1
O. Nilsson, M.D., Ph.D.,2 C.E. Jakobsson,3 B. Eliasson,3 S. Lindstedt, M.D., Ph.D.,3 L.E. Tisell, M.D., Ph.D.1
1Department of Surgery, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden
2Department of Pathology, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden
3Department of Clinical Chemistry, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden
Abstract. Adrenocortical carcinoma (ACC) is a rare disease with a poor prognosis. It has been difficult to establish a strict treatment program for ACC, and better treatment alternatives and diagnostic tools must be sought. Even though surgery is the treatment of choice, the role of surgery in advanced disease has been questioned. Eighteen consecutive patients were treated at our unit over a 22-year period (1975-1997). All patients underwent surgery and were followed by our protocol, which includes urinary steroid profiles, clinical examinations, analysis of steroid hormones, and radiologic investigations. Twelve patients received mitotane with drug concentration measurements to deliver an effective, nontoxic dose. The median duration of mitotane treatment was 12 months. Few side effects were observed. Four patients with low-stage tumors underwent second-look operations with no pathologic findings. Five patients were subjected to repeat operations, and the mean duration of the disease-free interval before repeat surgery for these patients was 59 months. There was a significant positive correlation between the disease-free interval and the observed survival after repeat surgery. Eleven patients with intentionally curative surgery had their urinary steroid profiles tested several times postoperatively. For five patients preoperative urine samples were also available. Steroid profiles indicated recurrent disease despite normal radiologic findings in two of these five patients. The follow-up ranged from 6 weeks to 24 years. The predicted 5-year survival was 58% according to the Kaplan-Meier method. We conclude that monitoring serum concentrations of mitotane makes long-term treatment possible with few side effects; steroid profile analysis can be used for early detection of tumor recurrence; and repeat surgery for recurrence is of value for patients with long disease-free intervals.
Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. The annual incidence is 0.5 to 2.0 per million inhabit- ants; that is, up to 16 new cases can be expected in Sweden each year [1]. Most of the ACC patients are referred to university hospitals, and different surgical strategies have been used; few multicenter trials have been performed. Reports of more than 50 patients from one institution are unusual.
In previous retrospective studies the overall 5-year survival was less than 30% with some improvement (35-46%) over the last decade [2-10]. The disease is often advanced at the time of diagnosis, and about half the patients have hormonal symptoms. The accuracy of diagnosis has been questioned [1] in some series
including that of small adrenocortical tumors referred to as “atypical adenomas.” Inclusion of potentially benign lesions has an impact on survival analysis.
Histologic indexes of malignancy that can predict prognosis have been elaborated [3, 11, 12, 32]. ACCs are usually aneuploid but may also be diploid. Therefore DNA ploidy is not a reliable indicator of diagnosis or prognosis [13, 14]. Some reports stress the poor prognosis in patients with large tumors and hormonal activity [11, 15], but multivariate analysis has failed to confirm this [2,5]. Others have noted a better prognosis in young patients and in those with certain patterns of steroid secretion (e.g., androgen or pregnenolone secretion) [5, 7]. The most severe prognostic factor is the presence of metastases.
Surgery is the treatment of choice for resectable primary and secondary tumors and for recurrent disease [2, 4, 8]. The role of adjuvant chemotherapy has been more controversial. Mitotane [o,p’-DDD: 1,1-dichloro-2-(o-chlorophenyl)-2(p-chlorophenyl)- ethane] has potent adrenolytic effects and may retard the growth of ACCs [16-18]. In a large retrospective multicenter study, mito- tane improved the survival rate only in patients with metastases [7].
Determination of urinary steroid profiles has been proposed as a sensitive tool for diagnosing ACC and for detecting recurrent disease [1, 19-23]. ACCs express several enzyme deficiencies in steroid biosynthesis, resulting in accumulation of intermediate metabolites, which can be detected by gas chromatography and mass spectrometry [15, 24, 25].
We report herein the results of an active treatment program in 18 consecutive patients with ACC (1975-1997). All patients were offered surgery. Recurrences were treated surgically if possible. From 1991 mitotane was recommended for all patients, and their urinary steroid profiles were monitored to facilitate early detec- tion of recurrence.
Materials and Methods
Patients
Eighteen consecutive patients with ACCs were operated on from January 1975 to December 1996 at the Department of Surgery, Sahlgrenska University Hospital, Göteborg, Sweden. The fol-
| Case no. (year of 1st operation) | Tumor stage (diameter, cm) | Extent of 1st operation | 2nd Look/site of recurrence | Extent repeat | Outcome (follow-up, months) |
|---|---|---|---|---|---|
| 3 (1979) | III (>5) | Adrenalectomy | 2nd Look | Exploration + biopsy | NED (71) |
| 9 (1989) | II (24) | Adrenalectomy | 2nd Look | Exploration + biopsy | NED (81) |
| 12 (1990) | II (11) | Adrenalectomy | 2nd Look | Exploration + biopsy | NED (78) |
| 16 (1996) | II (12) | Adrenalectomy | 2nd Look | Exploration + biopsy | NED (14) |
| 18 (1996) | II (6) | Adrenalectomy | Local + liver + lung | LE + DPE + SPLE | AWD (9) |
| 1 (1971) | II (10) | Adrenalectomy | Local + thorax | ATE + N + DPE + SPLE | NED (288) |
| 6 (1986) | IV (15) | Adrenalectomy + RLW | NED (136) | ||
| 11 (1990) | II (11) | Adrenalectomy | Local + caval vein | LE + CWR | DOD (42) |
| 17 (1996) | IV (17) | Adrenalectomy | DOD (3) | ||
| 14 (1993) | IV (5, 7) | Adrenalectomy, bilateral | DOD (14) | ||
| 5 (1984) | II (17) | Adrenonephrectomy | 1st Local | Excision | NED (159) |
| 2nd Local and liver | LE + DPE + LLE | ||||
| 8 (1986) | II (15) | Adrenonephrectomy | 1st Spine 2nd Local and liver | Laminectomy LE + LLE | DOD (72) |
| 7 (1986) | IV (15) | Adrenonephrectomy | DOD (9) |
LLE: liver lobectomy; LE: local excision; ATE: abdominothoracic excision; CWR: caval wedge resection; N: nephrectomy; DPE: distal pancreatectomy; SPLE: splenectomy; RLW: resection of liver wedge; NED: no evidence of disease; AWD: alive with disease; DOD: dead of disease.
low-up period ended with May 1997. Seventeen of the patients were primary cases, but one patient underwent a second operation during the period of study. The mean age at diagnosis was 53 ± 3 years (range 36-76 years). The female/male ratio was 0.8:1.0.
Surgical Treatment
All patients with ACC were surgically explored, and the adrenal tumor with surrounding soft tissue was excised en bloc. Thirteen patients had adrenalectomy alone or in combination with ne- phrectomy (Table 1). Five patients had more extensive operations (Table 2). When a recurrence was suspected because of clinical, radiologic, or biochemical changes, reexploration was done to excise the recurrence or to reduce the tumor burden. Reexplora- tion for recurrent disease was performed in five patients after a mean disease-free interval of 59 months (range 7-168 months) (Table 1). Four patients with stage II tumors without signs of recurrence underwent second-look operations (Table 1).
Medical Treatment
After 1991 twelve of fourteen patients were treated with mitotane after surgery, irrespective of tumor stage. The two exceptions (nos. 8 and 9) were older than 70 years and were hesitant to undertake therapy with potential side effects. The individual dose of mitotane was titrated by measuring the serum concentrations of the drug. Blood samples were obtained prior to the morning dose of mitotane. All patients on mitotane had cortisone replacement and sometimes fludrocortisone. Five patients (nos. 7, 8, 10, 11, 17) with a high-stage tumor or recurrent disease received additional treatment with radiation therapy (n = 1), cytotoxic drugs (strep- tozotocin, n = 4; doxorubicin, n = 1), or chemoembolization of the liver with doxorubicin (n = 1) or interferon (n = 1).
Morphologic Examinations
Tumor stage at the time of primary surgery was determined in all patients, using criteria according to MacFarlane and later inves- tigators [2, 29, 33]:
Stage I: tumor <5 cm in diameter and confined to the adrenals.
| Case no. (year of 1st operation) | Tumor stage (diameter, cm) | Extent of operation | Outcome (follow-up: months) |
|---|---|---|---|
| 4 (1981) | II (20) | A + N + DPE + SPLE | NED (176) |
| 15 (1996) | II (9) | A + N + SPLE | NED (16) |
| 2 (1976) | IV (>5) | A + N + DPE + SPLE + LLE | DOD (1.5) |
| 10 (1990) | IV (10) | A + LLE | DOD (4) |
| 13 (1991) | IV (13) | A + LLE + CWR | DOD (4) |
A: adrenalectomy; N: nephrectomy; DPE: distal pancreatectomy; SPLE: splenectomy; LLE: liver lobectomy; CWR: caval wedge resection; NED: no evidence of disease; AWD: alive with disease; DOD: dead of disease.
Stage II: tumor >5 cm in diameter and confined to the adrenals.
Stage III: tumor of any size with lymph node metastases or local invasive growth (i.e., tumor growth outside the adrenal but not involving adjacent organs).
Stage IV: tumor of any size with lymph node metastases and local invasive growth, growth into adjacent organs, or distant metastases.
Data for tumor staging were obtained by reexamining both the pathologic reports and specimens as well as reevaluating the radiologic findings and surgical reports. Only unequivocal positive findings of tumor spread were accepted, meaning that there is a possibility that some tumors may have been underscored as to stage.
Biochemical Methods
Steroid concentrations were measured by radioimmunoassay ex- cept pregnanetriol (gas chromatography) and 17-ketosteroids and 17-hydroxycorticosteroids (colorimetric assays using Zimmer- mann’s reaction). For the past 7 years complete urinary steroid profiles have been determined; the steroids were extracted by the method described by Schmidt et al. [21] and analyzed by gas chromatography and mass spectrometry (GC-MS) [1]. The con-
Khorram-Manesh et al .: Treatment and Follow-up of ACC
centration of mitotane in serum was measured by capillary gas chromatography [26].
Clinical Examinations and Follow-up Protocol
At diagnosis eight patients underwent both ultrasonography (US) and computed tomography (CT). Seven patients had only CT and two patients only US prior to surgery. Angiography was used in nine patients. During recent years angiography has been per- formed only in patients with large tumors in whom preoperative embolization was believed to minimize peroperative bleeding. Preoperative tumor embolization was done in two cases with suitable vascular anatomy. Patients with large right-sided tumors had a cavogram. The glomerular filtration rate of each kidney was determined separately by measuring the renal clearance of chro- mium-EDTA. Determination of urinary steroid profiles was in- troduced at our hospital in 1991, which led to fewer separate analyses of specific steroids in serum and urine [cortisol, aldoste- rone, dihydroepiandrosterone (DHEA)], unless hormonal symp- toms were present. After surgery the patients were followed at 3-month intervals during the first postoperative year. At follow-up visits a clinical examination was done, and urine was collected for steroid profiles. CT was done at 6-month intervals. After the first year patients without evidence of disease were followed at 6-month intervals.
In 1991 we started to recommend mitotane treatment postop- eratively to all patients with ACC concomitant with determination of the serum mitotane concentration. We tried to keep the concentration within the range of 14 to 20 µg/ml as recommended by Van Slooten [27]. During the first 3 months of treatment the patient had serum mitotane measurements every 1 to 2 weeks. These determinations helped us to keep the mitotane concentra- tion within the desired interval. Subsequent measurements were done every 3 to 6 months or on clinical suspicion of side effects.
Statistics
The predicted survival was calculated with the Kaplan-Meier method. Correlation was calculated as Pearson’s coefficient of correlation. All p values are two-tailed.
Results
The clinical manifestations of the disease in our patients were fatigue (56%), abdominal pain (50%), abdominal mass (33%), metastatic disease (28%), and hormonal syndromes (33%). Loss of libido was an early symptom in three men.
Patient Survival
One patient (no. 2) died of hepatic failure 6 weeks after major surgery. In the other patients both primary and the repeat operations were uneventful. The follow-up time ranged from 6 weeks to 24 years. The predicted 5-year survival according to the Kaplan-Meier method was 58% (Fig. 1).
The median follow-up of the eight patients who died of ACC was 0.5 year (range 0.13-6.0 years). The median observation time for the other 10 patients was 7.2 years (range 0.58-24.50 years). The five patients with repeat surgery for recurrent disease sur- vived for a mean of 55 months (range 2-120 months) after the
100
Estimated survival
80
percent
60
40
20
Time in years
0
0
1
2
3
4
5
Patients at risk 18
9
second operation. One of these patients is still alive without evidence of disease (no. 5), one died of other causes 10 years after repeat surgery (no. 1), one is alive with disease (no. 18), and two (nos. 8 and 11) died of ACC. The mean disease-free interval before repeat surgery for these five patients was 59 months. In this group of patients there was a significant positive correlation between the disease-free survival and the observed survival after repeat surgery (r = 0.95, p = 0.014).
Mitotane Therapy
The median dose of mitotane was 4 g (range 2.0-6.5 g), and the median serum mitotane concentration was 14.5 µg/ml (range 13-20 µg/ml). For this group of patients there was no correlation between the mitotane dose and the serum concentration of the drug. The median duration of mitotane treatment was 12 months (range 1-136 months). Possible adverse reactions appeared in five patients. Three patients (nos. 6, 8, 16) had nausea, one of whom had stage II disease with a negative second-look operation. She refused further medical treatment. One of the two other patients with nausea had also visual disturbances. The symptoms disap- peared in all patients after dose reduction. Two patients (nos. 7 and 12) had a skin rash that vanished during continued treatment. The association between the skin rash and the treatment is uncertain. Figure 2 illustrates the serum mitotane concentrations in a patient treated with this drug (no. 17). On a daily dose of 6.5 g of mitotane, nausea appeared and the dose had to be reduced. In this case it took about 20 weeks before the mitotane concentration had stabilized with a dose that did not cause side effects. In most patients it took 12 to 15 weeks before an individual dose without side effects was titrated.
Urinary Steroid Profiles
Twelve patients (nos. 1, 5, 6, 8, 9, 11-14, 16-18), who underwent intentionally curative surgery had their urinary steroid profiles determined several times postoperatively. For five of these pa- tients (nos. 13, 14, 16, 17, 18), preoperative urine samples were also available for analysis. Each steroid hormone can be deter- mined by GC-MS. Because there are no age- or sex-related normal values for this method, the steroid patterns of each
o,p -DDD concentration u g/ml
20
-7.0
Dose Mitotane
-4.5
gram/day
Dose Mitotane
-2.0
1
10-
o,p -DDD concentration
0
..
-0
0
10
20
30
40
50
Time in weeks
Pat. no 9
100
a THF
ES
A
IS
THE
%FS
11-HA
cortolone cortok
11-HE
P3
ø
Min
15.0
20.0
25.0
30.0
35.0
40.0
45.0
50.0
B
108
%.FS
e
Min
15.0
20.0
25.0
30.0
35.0
48.0
45.0
patients must be evaluated versus previous samples from the same patient. Patients with long observation periods without recurrent disease had steroid profiles identical with those in their first postoperative urine collections (Fig. 3, no. 9). However, one patient with virilism (no. 12) developed a selective increase in the secretion of pregnanediol, pregnanetriol, and androstenetriol, which led to reoperation with normal macroscopic findings. In subsequent samples these steroids were again reduced. Four years later this patient is without evidence of recurrent disease.
In two of five patients with pre- and postoperative urine samples the steroid profiles indicated recurrent disease despite normal radiologic findings. One patient (no. 13) had normal radiologic findings after primary surgery. However, production of high amounts of 3-ß-hydroxy-5-ene steroids persisted and rapidly increased. The patient died of disseminated disease 4 months later. The other patient (no. 18) had a rapid recurrence with a steroid pattern typical of the original tumor (Fig. 4). She was reoperated 6 months later when she had positive radiologic findings and disseminated disease. One patient (no. 17) with a pathologic preoperative steroid profile underwent surgical exci-
Pat. no 18
1 00
a THF
11-HA
cortolone
A
THE -
+cortole
11-HE
ES
O
P3
pregnenadiol
P2
IS
androstenetriol
ATS
E/A
N
9
16 a-OH-DHA
Min
15.0
20.º
25.º
32.0
35.0
12.1
1.0
P.
×1.5
B
100
%7$
9
Min
150
20.0
5.0
10.0
35.0
10,0
15.0
FINO
100
×2
.
C
%JS
.
MIT
1.0
20.0
2.º
2.0
35.0
The
15.0
P.
100
.
×1.6
D
ZFS
.
Min
15.0
20.0
23.0
39.9
35.0
19.9
15.0
30.0
sion of the primary tumor with residual liver metastases. The steroid profile after surgery showed diminished secretion of androgens (androsterone, etiocholanolone, DHEA, and 11-hy- droxyandrosterone), but there was persistence of pregnanediol,
Pat. no 17
100
×3.0
a THF
A
THE
cortolone
pregnenediol
THS
cortole
o pregnenetriol
11-HE
0
O androstenetriol
IS
11-HA
P3
ES
ATS
P21
E/A
O
.
Min
15,9
20.0
25.0
30.0
35.0
10.9
15.0
50.0
100
×3.0
B
XFS
9
Min
15.0
20.0
25.0
30.0
35.0
10.0
15,0
50.0
pregnanetriol, pregnenediol, pregnenetriol, and secretion of glu- cocorticoids and metabolites (tetrahydrocortisone/cortisol, cor- tolone and cortoles) (Fig. 5). These findings suggest the primary tumor as the source of androgen production.
Discussion
In this limited series we found that tumor stage at the time of the first operation was an important prognostic factor. Henley et al. [2] reported that the 5-year survival doubled (up to 32%) if patients with ACC underwent intentionally curative resection even though tumor tissue was present outside the adrenals (stage III and IV disease), which was the case in two-thirds of their patients. Cohn et al. [4] also reported enhanced survival rates with active surgical treatment. One-third of their 47 patients had stage II and IV tumors with mean survival times of 5.0 and 2.3 years, respectively, which agrees well with our survival rates:
Stage II: eight patients alive (seven disease-free, one with residual disease) and two patients dead of disease; mean survival time 7.8 years
Stage III: one patient dead of other causes, with no evidence of disease at a postoperative follow-up of 5.9 years.
Stage IV: one patient with long survival (>10 years); mean survival for six patients dead of disease was 2.0 years.
In a French multicenter study [7] the mean survival times for stage I, II, III, and IV tumors were 34, 40, 22, and 8 months, respec- tively. At the end of our study 8 of 18 patients had died of ACC.
| Study | Year | Overall no. of patients | Overall survival (%) |
|---|---|---|---|
| Didolkar et al. [28] | 1981 | 42 | 24 |
| Nader et al. [34] | 1983 | 77 | 30 |
| Henley et al. [2] | 1983 | 62 | 16 |
| Venkatesh et al. [6] | 1989 | 110 | 23 |
| Gröndal et al. [1] | 1990 | 54 | 19 |
| Icard et al. [7] | 1992 | 156 | 34 |
| Pommier and Brennan [8] | 1992 | 73 | 35 |
| Current study | 1997 | 18 | 58 |
The deceased survived only for a mean of 0.5 years after surgery, whereas the others were observed for a mean of 7.2 years.
The predicted 5-year survival of 58% in our series equals that in the best published results [2, 7, 8] (Table 3). It has been reported that ACC recurrence can appear as long as a decade after the initial operation [29]. In this study one patient (no. 1) had a recurrence 14 years after initial surgery. Five of our patients had repeat operations for recurrence. Before repeat surgery these patients had a mean survival of 59 months. The observed survival after repeat surgery averaged 55 months. The length of the observed survival was positively correlated to the disease-free interval after the initial operation.
Our findings thus indicate that patients with long disease-free intervals after primary surgery benefit from repeat surgery. With stage II disease the prognosis in our series was good. Second-look laparotomy in four such patients without biochemical or radio- logic evidence of recurrent disease could not identify any tumor tissue. One patient with stage II disease rapidly developed an aberrant urinary steroid profile following the primary operation, indicating recurrent disease. This biochemical signal did not lead to reexploration until radiologic signs were present 3 months later, when disseminated disease was found.
The urinary steroid profile is a tool with the potential of early identification of recurrent disease, as also evidenced in one patient with stage IV disease subjected to intentionally curative surgery. The use of steroid profiles are still limited owing to a lack of age- and sex-distributed reference values and of identification of truly pathologic intermediate metabolites. Lipsett et al. [15] suggested that relative enzyme deficiencies in the steroid meta- bolic pathway were more common in patients with ACC than in those with benign adrenocortical disease. Gröndal et al. [1] used GC-MS in their investigation of urinary steroid profiles of 24 patients with ACC. Of these patients, 23 had elevated levels of tetrahydro-11-deoxycortisol, 3-ß-hydroxy-5-enesteroids, or both compared with a small reference material. Most of the ACC patients had hormonal symptoms.
Effective adjuvant medical therapy for ACC patients has long been sought. The literature on the adrenolytic drug mitotane as an antineoplastic agent is contradictory. In early studies high tumor regression rates were reported (61%), little influencing median survival [16]. High-dose regimens (6-10 g) were also tested without convincing effects, but they led to side effects in the gastrointestinal tract and the central nervous system [30]. Because of severe side effects lower doses (2 g) were recommended to all patients with ACC [17]. A group in Leiden in 1984 introduced the determination of serum mitotane levels [27]. They found that
seven of eight responders had serum levels exceeding 14 µg/ml and 19 of 20 nonresponders had levels less than 10 µg/ml, suggesting a critical therapeutic interval. Because the drug can be metabolized in several ways, it seems logical to monitor the individual drug concentration in each patient to reach the thera- peutic interval using the lowest possible effective dose without side effects, as demonstrated in this study (median level 14.5 µg/ml, range 13-20 µg/ml). In the large French multicenter study, mitotane significantly improved survival in patients with metasta- ses who received the drug subsequent to surgery. In the dosage used (3-4 g daily, not more than 8 g/day), the drug had relatively high patient compliance [7]. Haak et al. [9] evaluated the efficacy of mitotane treatment of 96 patients treated between 1959 and 1992. In this series complete tumor resection was achieved in 49% and subtotal resection in 39%. Adjuvant mitotane treatment did not influence the results after total resection. In all, 62 patients were given mitotane at some time during their disease. High mitotane levels (>14 µg/ml) was shown to be an independent factor that influenced survival favorably. The recent finding that multidrug resistance mediated by MDR-1/P glycoprotein can be reversed by mitotane suggests the use of mitotane in combination with other chemotherapeutic agents for patients with advanced ACC. In multicenter trials of such patients of the South Western Oncology Group (SWOG) the combination of mitotane and cisplatin resulted in tumor regression in one-third of patients [31].
Conclusions
We conclude from this study that active surgical treatment, with reoperation at signs of recurrence, is most important to obtain optimal survival and symptom palliation for ACC patients. Re- peat surgery for recurrence is especially valuable in patients with a long disease-free interval. In this limited material we cannot evaluate the effects of adjuvant mitotane therapy, either as a potential prophylactic drug or as an antineoplastic agent. How- ever, no objective tumor regression was observed in any of the patients. Because of the side effects of the drug, we advocate close monitoring of serum concentrations of mitotane in individual pa- tients. The diagnostic value of urinary steroid profiles is promising, but to be able to evaluate this tool coordinated multicenter investi- gations and assembly of a solid reference material are required.
Résumé
Le cancer de la corticosurrénale (CCS) est rare, son pronostic est mauvais. Un attitude thérapeutique stricte est difficile à établir; aussi a t’on cherché à trouver des alternatives thérapeutiques et de meilleurs outils diagnostiques. Bien que la chirurgie soit le traitement de choix, le rôle de la chirurgie en cas de maladie avancée reste problématique. Dix-huit patients consécutifs ont été opérés dans notre unité pendant 22 ans (1975-1997). Tous les patients ont été suivis par notre programme de surveillance comprenant des dosages stéroïdiens urinaires, des examens clin- iques, une analyse des hormones stéroïdiennes et des examens radiologiques. Douze patients ont reçu du mitotane dont les concentrations ont été contrôlées afin d’assurer une dose efficace et non-toxique. La durée médiane du traitement a été de 12 mois avec très peu d’effets secondaires. Quatre patients avec des tumeurs de bas grade ont eu des interventions «second-look» sans trouver de maladie évolutive. Cinq patients ont eu une deuxième
intervention après une durée moyenne sans maladie de 59 mois. La survie après chirurgie secondaire était corrélée de façon significative avec la durée de survie sans maladie avant la reprise. Onze patients avec chirurgie à visée curative ont eu des examens urinaires plusieurs fois en postopératoire. Les résultats des exa- mens d’urines préopératoires étaient disponibles pour 5 patients. Les résultats étaient en faveur d’une reprise évolutive malgré des investigations radiologiques négatives chez 2 de ces 5 patients. La durée du suivi allait de 6 semaines à 24 ans. La survie à 5 ans attendu a été de 58% selon la méthode de Kaplan-Meier. Nous concluons que 1) le monitoring des concentrations sériques du mitotane rend possible un traitement au long cours avec peu d’effets secondaires; 2) l’analyse des métabolites stéroïdiens peut être utile pour détecter la récidive tumorale à un stade précoce, et 3) la chirurgie itérative pour récidive est valable pour les patients ayant un long intervalle sans maladie.
Resumen
El adenocarcinoma adrenocortical (CAC) es una enfermedad poco frecuente y de mal pronóstico, para la cual ha sido muy difícil establecer un programa estricto de tratamiento; se hace necesario investigar nuevas alternativas terapéuticas, así como nuevos métodos diagnósticos. Aunque la cirugía constituye el tratamiento de escogencia, se ha cuestionado su papel en los casos de enfermedad avanzada. Dieciocho pacientes consecutivos fu- eron tratados en nuestro servicio en un periodo de 22 años (1975-1997). Todos los casos fueron sometidos a intervención quirúrgica y seguidos según nuestro programa, el cual incluyó perfiles de esteroides urinarios, exámenes clínicos, análisis de hormonas esteroideas e investigaciones radiológicas. Doce paci- entes recibieron mitotano con mediciones de la concentración plasmática de la droga con el fin de lograr dosis efectivas y no tóxicas. La duración media del tratamiento con mitotano fue de 12 meses; se registraron muy pocos efectos secundarios. En cuatro pacientes con tumores en estados menores se practicaron reex- ploraciones de control (“second look”), con hallazgos patológicos negativos. Cinco fueron sometidos a operaciones repetidas, siendo 59 meses el intervalo medio del estado libre de enfer- medad antes de la cirugía repetida. Se encontró una correlación significativamente positiva entre el intervalo libre de enfermedad y la supervivencia luego de la cirugía repetitiva. En once casos que tuvieron cirugía intencionalmente curativa se practicaron perfiles de esteroides urinarios en varias oportunidades en el curso del seguimiento postoperatorio. En cinco casos también se dispuso de muestras urinarias preoperatorias. Los perfiles de esteroides revelaron enfermedad recurrente en dos de los 5, a pesar de hallazgos radiológicos normales. El periodo de seguimiento osciló entre 6 semanas y 24 años. La supervivencia predecible a 5 años, según el método de Kaplan-Meier, fue de 58%. Nuestras conclu- siones son las siguientes: 1) La monitoría de los niveles séricos de mitotamo permite realizar un tratamiento a largo lazo con escasos efectos secundarios; 2) El análisis de los perfiles de esteroides puede ser utilizado para la detección temprana de recurrencia tumoral; iii) La cirugía repetitiva es de valor en el manejo de recurrencias en los pacientes con periodos prolongados libres de enfermedad.
Khorram-Manesh et al .: Treatment and Follow-up of ACC
Acknowledgments
This work was supported by grants from the Swedish MRC (5520), Göteborg Medical Society, A. Gabrielsson Foundation, and Sahl- grenska Hospital Research Funds.
References
1. Gröndal, S., Cedermark, B., Eriksson, B., Grimelius, L., Harach, R., Kristoffersson, A., Rastad, J., Udèn, P., Åkerström, G .: Adrenocorti- cal carcinoma: a retrospective study of a rare tumor with a poor prognosis. Eur. J. Surg. Oncol. 16:500, 1990
2. Henley, D.J., van Heerden, J.A., Grant, C.S., Carney, J.A., Carpenter, P.C .: Adrenal cortical carcinoma: a continuing challenge. Surgery 94:926, 1983
3. Van Slooten, H., Schaberg, A., Smeenk, D., Moolenar, A.J .: Morpho- logical characteristics of benign and malignant adrenocortical tu- mours. Cancer 55:766, 1985
4. Cohn, K., Gottesman, L., Brennan, M .: Adrenocortical carcinoma. Surgery 100:1170, 1986
5. Luton, J.P., Cerdas, S., Billand, L., Thomas, G., Guihaume, B., Bertagna, X., Landat, M.H., Louvel, A., Chapuis, Y., Blandeau, P., Bonnin, A., Bricaire, H .: Clinical features of adrenocortical carci- noma, prognostic factors and the effect of mitotane therapy. N. Engl. J. Med. 322:1195, 1990
6. Venkatesh, S., Hickey, R.C., Sellin, R.V., Fernandez, J.F., Samaan, N.A .: Adrenal cortical carcinoma. Cancer 64:765, 1989
7. Icard, P., Chapuis, Y., Andreassian, B., Bernard, A., Proye, C .: Adrenocortical carcinoma in surgically treated patients: a retrospec- tive study on 156 cases by the French Association of Endocrine Surgery. Surgery 112:972, 1992
8. Pommier, R.F., Brennan, M.F .: An eleven year experience with adrenocortical carcinoma. Surgery 112:963, 1992
9. Haak, H.R., Hermans, J., van de Valde, C.J.H., Lentjes, E.G.W.M., Goslings, B.M., Fleuren, G.J., Krans, H.M.J .: Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br. J. Cancer 69:947, 1994
10. Kasperlik-Zaluska, A.A., Migdalska, B.M., Zgliczynski, S., Makowska, A.M .: Adrenocortical carcinoma: a clinical study and treatment result of 52 patients. Cancer 75:2587, 1995
11. Hough, A.J., Hollifield, J.W., Page, D.L., Hartmann, W.H .: Prognostic factors in adrenal cortical tumors. Am. J. Clin. Pathol. 72:390, 1979
12. Weiss, L.M .: Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol. 8:163, 1984
13. Medeiros, L.J., Weiss, L.M .: New developments in the pathologic diagnosis of adrenal cortical neoplasms. Am. J. Clin. Pathol. 97:73, 1991
14. Lee, J.E., Berger, D.H., El-Naggar, A.K., Hickey, R.C., Vassilopou- lou-Sellin, R., Gagel, R.F., Burgess, A.M., Evans, D.B .: Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118:1090, 1995
15. Lipsett, M.B., Hertz, R., Ross, G.T .: Clinical and pathophysiologic aspects of adrenocortical carcinoma. Am. J. Med. 35:374, 1963
16. Lubitz, J.A., Freeman, L., Okun, R .: Mitotane use in inoperable adrenal cortical carcinoma. J.A.M.A. 223:1109, 1973
17. Schteingart, D.E., Motazedi, A., Noonan, R.A., Thompson, N.W .: Treatment of adrenal carcinoma. Arch. Surg. 117:1142, 1982
18. Kintzer, P.P., Peterson, M.E .: Mitotane treatment of 32 dogs with cortisol secreting adrenocortical neoplasms. J. Am. Vet. Med. Assoc. 205:54, 1994
19. Axelson, M., Sahlberg, B.L., Sjövall, J .: Analysis of profiles of conju- gated steroids in urine by ion-exchange separation and gas chroma- tography-mass spectrometry. Chromatogr. Biomed. Appl. 224:355, 1981
20. Minowada, S., Kinosluta, K., Hara, M., Isurugi, K., Vehikawa, T., Niijima, T .: Measurement of urinary steroid profile in patients with adrenal tumor as screening method for carcinoma. Endocrinol. Jpn. 32:29, 1985
21. Schmidt, N.A., Borburgh, H.J., Penders, T.J., Weykamp, C.W .: Ste- roid profiling: an update. Clin. Chem. 31:637, 1985
22. Homoki, J., Hol, R., Teller, W.M .: Harnsteroid Profile bei Cushing Syndrom und Tumoren der Nebennierenrinde. Klin. Wochenschr. 65:719, 1987
23. Weykamp, C.W., Penders, T.J., Schmidt, N.A., Borbourgh, A.J., van de Calseyde, J.F., Wolthers, B.J .: Steroid profile for urine: reference value. Clin. Chem. 35:2281, 1989
24. Degenhardt, H.J., Drop, S.L.S., Hoogerbrugge, J., van Seters, A.P., de Vries, H.R .: In vitro studies of enzymatic activities in human adrenal tumors. Horm. Res. 16:96, 1982
25. Doerr, H.G., Sippell, W.G., Drop, S.L.S., Bidlingmaier, F., Knorr, D .: Evidence of 11-ß-hydroxylase deficiency in childhood adrenocortical tumor. Cancer 60:1625, 1987
26. Moolenaar, A.J., Niewint, J.W.M., Oei, I.T .: Estimation of o,p’-DDD in plasma by gas liquid-chromatography. Clin. Chem. Acta 76:213, 1977
27. Van Slooten, H., Moolenaar, A.J., Van Seters, A.P., Smeenk, D .: The treatment of adrenocortical carcinoma with o,p’-DDD: prognostic implications of serum level monitoring. Eur. J. Cancer Clin. Oncol. 20:47, 1984
28. Didolkar, M.S., Bescher, A., Elias, E.G., Moor, R.H .: Natural history of adrenal cortical carcinoma. Cancer 47:2153, 1981
29. Sullivan, M., Bojkan, M., Hodges, C.V .: Adrenal cortical carcinoma. J. Urol. 120:660, 1978
30. Hoffman, D.L., Mattox, V.R .: Treatment of adrenocortical carcinoma with o,p’-DDD. Med. Clin. North Am. 56:999, 1972
31. Dogliotti, L., Berruti, A., Pia, A., Paccotti, P., Ali, A., Angeli, A .: Cytotoxic chemotherapy for adrenocortical carcinoma. Minerva En- docrinol. 20:105, 1995
32. Weiss, L.M., Medeiros, L.J., Vickery, A.L .: Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 13:202, 1989
33. MacFarlane, D.A .: Cancer of the adrenal cortex: the natural history, prognosis and treatment in a study of fifty-five cases. Ann. R. Coll. Surg. Engl. 23:155, 1958
34. Nader, S., Hickey, R.C., Sellin, R.V., Samaan, N.A .: Adrenal cortical carcinoma: a study of 77 cases. Cancer 52:707, 1983
Invited Commentary
Murray F. Brennan, M.D.
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Adrenocortical carcinoma is an uncommon neoplasm and re- mains a significant challenge for physician, surgeon, and patient. Efficacious treatment has improved little over the last 20 years.
Complete surgical resection remains the mainstay for both pri- mary and recurrent disease; but cure, once metastasis is estab- lished, is virtually unheard of. Occasional long-term stabilization is seen in patients with metastatic disease, as with other neuroen- docrine tumors.
This manuscript from Göteborg emphasizes many of these points. Eighteen patients were treated over a period of 22 years, emphasizing the rarity of the disease. All patients underwent operation, and 12 patients received mitotane for a median dura- tion of 12 months. The paper addresses three issues: (1) the value
of mitotane; (2) the value of surgical resection for recurrence; and (3) monitoring the urinary steroid profile for the detection of recurrence.
The authors used angiography in nine patients and argue that it may be of value in preoperative embolization. Only two patients were embolized, and most centers would not utilize this approach, given the extensive vascular supply and the rare tumor that has a single arterial supply.
Five of eighteen operated patients underwent reexploration for recurrence, two of whom had no evidence of disease (NED) at the time of follow-up. Four patients underwent elective second-look operations, but nothing was found, and they all remained NED. Twelve of fourteen patients received mitotane, the indications for which were unclear. Evaluation of the effect was confused by additional treatment in five. The authors have a surprisingly aggressive follow-up program, with urinary steroid profiles every 3 months and CT every 6 months. This is difficult to understand, as elective second-look operations did not find any recurrence and only two of five patients were NED after reoperation for recur- rence. It is unclear whether this aggressive approach detected recurrence earlier than it might have been found based on clinical or even simple serum analysis of, for example, DHEAS, given the small number of patients and the poor outcome for any recur- rence. The argument for vigorous steroid excretion evaluation is difficult to sustain. One patient had virilism and elevated urine levels, but nothing was found at operation. There was no subse- quent recurrence. Two patients with early urinary steroid recur-
rence had no radiologic findings, but at operation they had disseminated disease and were not helped.
Use of mitotane was monitored with serum levels, which required weekly measurements for the first 3 months to keep mitotane at a “desired interval.” This again appears to be expen- sive, and it is unclear what the justification is for 14 to 20 µg/ml as the desired concentration. The dose of mitotane utilized would be considered low by most authors. The range, 2.0 to 6.5 g, is not proportional to the serum concentration of the drug. This is consistent with the fact that only 5 of 12 patients had any symptomatic side effects. Three consisted of nausea. The low incidence of side effects is consistent with the low dose of the drug.
In summary, the authors highlight the problems associated with adrenocortical carcinoma. The disease is rare, it is often advanced at the time of presentation, operation provides the only chance for survival, and with selected patients reoperation may prolong survival. Not surprisingly, overall survival in patients with recur- rence is influenced by disease-free survival.
I do not believe the authors have provided any proof that the extensive use of urinary steroid profiles necessarily identifies early disease or, if it does, influences outcome. In addition, the data suggest that extensive use and monitoring of serum levels of mitotane as a benefit to the patient is not supported. In fact, by the authors’ own claim, “adjuvant mitotane treatment did not influ- ence the results after resection.” Unfortunately, we need new therapeutic strategies rather than minor manipulation of current approaches.